Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913632 | 1.00 | SYK (0.62) | SYKEGFRBRD4STAT6KDM4E | |
| SCHEMBL913769 | 0.93 | SYK (0.62) | SYKEGFRMAPK8MAPK9ULK1 | |
| SCHEMBL913767 | 0.93 | SYK (0.62) | SYKEGFRMAPK8MAPK9ULK1 | |
| SCHEMBL912948 | 0.92 | SYK (0.61) | SYKEGFRSTAT6MAPK8MAPK9 | |
| SCHEMBL912945 | 0.92 | SYK (0.61) | SYKEGFRSTAT6MAPK8MAPK9 | |
| SCHEMBL912659 | 0.91 | SYK (0.62) | SYKEGFRSTAT6MAPK8MAPK9 | |
| SCHEMBL912660 | 0.91 | SYK (0.62) | SYKEGFRSTAT6MAPK8MAPK9 | |
| SCHEMBL913968 | 0.90 | SYK (0.59) | SYKEGFRBRD4STAT6MAPK8 | |
| SCHEMBL913969 | 0.90 | SYK (0.59) | SYKEGFRBRD4STAT6MAPK8 | |
| SCHEMBL914265 | 0.90 | SYK (0.60) | SYKEGFRMAPK8MAPK9MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885EGFR 772/4885BRD4 1961/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885EGFR 772/4885BRD4 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.